Pierre Fabre Partners with XtalPi for AI-Driven Robotics in Drug Discovery

On November 9, 2026, Laboratoires Pierre Fabre and XtalPi announced a partnership to identify novel small-molecule clinical candidates in oncology and potentially dermatology or rare diseases. XtalPi will handle de novo molecular design with its integrated AI and robotic platform, while Pierre Fabre will screen compounds and manage subsequent clinical development. The agreement includes upfront payments, milestone fees, and revenue sharing to accelerate discovery for historically difficult targets.

On November 9, 2026, Laboratoires Pierre Fabre and XtalPi announced an agreement to discover novel small-molecule clinical candidates using XtalPi's integrated AI capabilities and robotics platform. The collaboration focuses on oncology, dermatology, and rare diseases, where XtalPi handles de novo molecular design while Pierre Fabre manages compound selection and subsequent development. This partnership aims to accelerate the identification of high-quality clinical candidates for historically difficult drug targets through a combined approach of AI-enabled design and disease biology expertise.